Literature DB >> 14579791

The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture.

Victor Tse1, Lei Xu, Yun C Yung, Justin G Santarelli, David Juan, Klaus Fabel, Gerald Silverberg, Griffith Harsh.   

Abstract

Angiopoietins play a pivotal role in tumor angiogenesis by modulating vascular endothelial proliferation and survival. The expression of angiopoietins 1 and 2 (Ang-1 and Ang-2) and vascular endothelial growth factor (VEGF) has been documented in human malignant glioma. The expression of Ang-1, Ang-2, VEGF, and Tie-2, a member of the receptor tyrosine kinases and the natural receptor for both Ang-1 and Ang-2, follows a distinct transcriptional profile in vivo. Ang-2 and VEGF were expressed early in tumor formation and their levels increased throughout tumor growth. Their expression coincided with the expansion of the tumor mass and the formation of the vascular tree. There was no significant change in the expression of Tie-2 and Ang-1. The expression of Ang-1 and Tie-2 was more noticeable at the periphery of the tumor. The expression of Ang-2 was more robust at the periphery and within the tumor mass, and VEGF was more concentrated within the center of the tumor. This distinct expression profile may explain the morphology of the newly formed vessels at various times and regions of the tumor. The lack of concomitant expression of Ang-1 may underscore the unopposed endovascular induction by Ang-2 and VEGF resulting in the chaotic appearance and fragility of tumor vessels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579791     DOI: 10.1179/016164103101202084

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

1.  Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding.

Authors:  Corey E Tabit; Phetcharat Chen; Gene H Kim; Savitri E Fedson; Gabriel Sayer; Mitchell J Coplan; Valluvan Jeevanandam; Nir Uriel; James K Liao
Journal:  Circulation       Date:  2016-06-28       Impact factor: 29.690

Review 2.  Genetic and hypoxic regulation of angiogenesis in gliomas.

Authors:  Balveen Kaur; Chalet Tan; Daniel J Brat; Dawn E Post; Erwin G Van Meir
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

3.  Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer.

Authors:  Maho Kumagai; Mitsuji Nagahama; Yumiko Akamine; Tomoko Ozeki; Akifumi Suzuki; Kiminori Sugino; Koichi Ito; Masatomo Miura
Journal:  Cancer Diagn Progn       Date:  2022-05-03

Review 4.  Stem cell therapy for chronic heart failure: an updated appraisal.

Authors:  Simon Maltais; Steven J Joggerst; Antonis Hatzopoulos; Thomas G DiSalvo; David Zhao; Hak-Joon Sung; Xintong Wang; John G Byrne; Allen J Naftilan
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 5.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

6.  Computational modeling of tumor response to vascular-targeting therapies--part I: validation.

Authors:  Jana L Gevertz
Journal:  Comput Math Methods Med       Date:  2011-03-23       Impact factor: 2.238

7.  Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis.

Authors:  Zijing Lin; Yu Liu; Yuhui Sun; Xiuping He
Journal:  J Exp Clin Cancer Res       Date:  2011-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.